Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service carotid revascularization cases in Kansas: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (200 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 19 | 643 | 20% |
| 2020 | 14 | 594 | 23% |
| 2021 | 15 | 591 | 28% |
Carotid endarterectomy and stenting including TCAR. Professional codes (what the surgeon bills): CPT 35301, 37215.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 80% of the cases CMS names in Kansas; 10 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Peripheral arterial intervention | 13 | 2,258−6.3%/yr | −6.3%/yr | 5.41.3× | 53% | 2,010 in 2030−1.9%/yr |
| Dialysis access |
Carotid revascularization in every state, and its device makers · Every procedure market in Kansas · Every state · Compare with Illinois
| ≈ 570 |
| – |
| 2026 est. | ≈ 570 | – |
| 2022 | 15 | 608 | 31% |
| 2023 | 15 | 568 | 34% |
| 2024 | 16 | 530 | 36% |
| 2025 from claims | – | 568 459–667 | 36% |
| 2026 forecast | – | 574 450–721 | 36% |
| 2027 forecast | – | 580 430–767 | 36% |
| 2028 forecast | – | 586 415–809 | 37% |
| 2029 forecast | – | 592 403–849 | 37% |
| 2030 forecast | – | 598 392–888 | 37% |
In 2025, 100% inpatient hospital.
| −6.8%/yr |
| 1.1 |
| 0% |
| 1,200 in 2030−0.6%/yr |
| Missouri | 24 | 999−5.5%/yr | −5.5%/yr | 1.6 | 0% | 1,110 in 2030+1.7%/yr |
| Michigan | 13 | 961−9.4%/yr | −9.4%/yr | 1.1 | 0% | 870 in 2030−1.7%/yr |
| Indiana | 20 | 960−7.3%/yr | −7.3%/yr | 1.3 | 0% | 930 in 2030−0.5%/yr |
| Wisconsin | 15 | 618−4.6%/yr | −4.6%/yr | 1.1 | 0% | 730 in 2030+2.8%/yr |
| Minnesota | 6 | 404−8.6%/yr | −8.6%/yr | 0.9 | 0% | 530 in 2030+4.6%/yr |
| Iowa | 11 | 376−4.9%/yr | −4.9%/yr | 0.8 | 0% | 380 in 2030+0.3%/yr |
| Nebraska | 5 | 321−9.6%/yr | −9.6%/yr | 1.2 | 0% | 410 in 2030+4.2%/yr |
| South Dakota | 10 | 315+2.9%/yr | +2.9%/yr | 2.4 | 0% | 470 in 2030+6.9%/yr |
| North Dakota | 3 | 119−14%/yr | −14%/yr | 1.2 | 0% | 380 in 2030+21%/yr |
| 17 |
| 1,438−10%/yr |
| −10%/yr |
| 3.60.8× |
| 63% |
| 1,570 in 2030+1.4%/yr |
| Superficial venous ablation | 15 | 766−21%/yr | −21%/yr | 1.80.5× | 38% | 870 in 2030+2.2%/yr |
| Thrombectomy, IVC filters & venous stents | 2 | 454+4.3%/yr | +4.3%/yr | 1.10.8× | 0% | 920 in 2030+12%/yr |
| Aortic endografts (EVAR/TEVAR) | 3 | 178−7.8%/yr | −7.8%/yr | 0.40.9× | 0% | 160 in 2030−1.9%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Boston Scientific leads with 89% of company spending on these surgeons in 2025, −7 pts on 2024.
In 2025, 2 companies reported engagement with Kansas’s surgeons worth $1,692 in consulting, speaking, meals and travel tied to these products, about $106 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 19 clearances and approvals in the category, 7 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.